Moderna, Inc. - Common Stock (MRNA)

Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week.

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 10.2% in the afternoon session after the company published positive Phase 3 clini...

Moderna Inc (NASDAQ: MRNA) shares are trading higher Friday morning as traders react to peer reviewed Phase 3 flu-vaccine data.

Moderna’s first quarter was marked by a sharp increase in revenue, driven by the fulfillment of large international contracts, particularly through a strateg...

Moderna, Inc. (NASDAQ:MRNA) shares initially surged Thursday, but have since retreated after the company announced the publication of its Phase 3 study results evaluating mRNA -1010 in the New England Journal of Medicine.

Biotechnology company Moderna (NASDAQ:MRNA) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 260% year on year to $389 mil...

Moderna (MRNA) Q1 2026 Earnings Transcript

Biotechnology company Moderna (NASDAQ:MRNA) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 260% year on year to $389 mi...

Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Friday morning. Here’s what you need to know. Moderna beat analysts’ revenue expec...

These companies offer a clear path to sustained earnings growth.

It will be a turbulent ride, but patient investors might come out of it much richer.

Moderna (NASDAQ:MRNA) shares are moving higher on Monday after the company won FDA Fast Track status for an oncology program.

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...